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Author's Reply
I am grateful to David Bell for extending the discussion on the role of RDT for malaria diagnosis. As with most nonsubjective tests, the application of any new technology must be examined to find its place in clinical diagnosis in any given area.
The areas where malaria is nonendemic do require a test system that will detect any parasitemia present, and as the majority of the population in these areas are nonimmune, the question of the subpatent infections is usually not encountered. In these circumstances the most sensitive method available for malaria detection is still microscopy, and RDTs are slowly finding a role in the laboratory when expert microscopy is not available. Short-term posttreatment monitoring with RDTs can be of significant value. Persisting antigen detection with HRPII may confuse treatment monitoring but can be useful when unknown therapy for a clinical diagnosis for malaria has been given prior to returning home.
I agree with David Bell that areas where malaria is endemic present a greater challenge for the RDT. Subpatent and fluctuating parasitemia are present and may present a diagnostic challenge but are frequently asymptomatic and are necessary for retaining the antigenic stimuli for protective immunity. The current sensitivity of RDTs for primary diagnosis may not be adequate to reflect all levels of parasitemia present but should not "overdiagnose" parasitemias from asymptomatic cases. This is a very sensitive balance, and because most acute malaria in areas of endemicity occurs among children, the use of RDTs in these circumstances may not be sufficiently sensitive to replace microscopy at present. Detecting persistent antigenemia by using HRPII-based RDTs does have a role in epidemiological awareness, but at present they are not capable of differentiating between a continuing asexual parasitemia and gametocytemia.
The current format of available RDTs presents two possible diagnostic tools. RDTs that detect parasite enzymes are sensitive diagnostic tools that can also be used to monitor a declining parasitemia with viable parasites; this may not be economically feasible in all circumstances but is technically available and clinically useful. Parasite enzymes tend not to be present beyond clearance of peripheral blood parasites and parallel most closely the microscopic findings.
Tests based on detection of P. falciparum HRPII antigen are also sensitive tools, but antigenemia can persist beyond clearance of asexual parasitemia. Persistence of HRPII can be found with residual gametocytes, which may present a public health risk for continued malaria transmission in areas of endemicity but may present a conundrum to physicians in case of failed therapy. In some areas where malaria is endemic, attempts are made to try to eliminate the gametocyte risk by treating patients with an appropriate secondary drug. I know of no study that has been made to evaluate the detection of gametocytes alone using RDTs, and perhaps this issue needs to be examined.
I am aware that the next generation of enzyme-based RDTs will offer a more useful malaria speciation option. I agree that the questions of improving sensitivity and examining the presence of persistent gametocytemia detection, along with costing stability, should be foremost in the malaria RDT development program for diagnostic products. The difficult question of "approval for use" in certain countries is also being addressed by manufacturers in Europe, but Food and Drug Administration approval has not yet been given to these products.
